Int J Biometeorol:述情障碍会提高皮肤疾病发病率

2022-07-22 医路坦克 MedSci原创

述情障碍(alexithymia)又译作“情感表达不能”或“情感难言症”,本文主要介绍述情障碍在皮肤科患者中的发病情况,进一步调查述情障碍对疾病负担、社会心理共病和治疗的影响。

述情障碍(alexithymia)又译作“情感表达不能”或“情感难言症”,它并非一种独立的精神疾病,可为一种人格特征,也可为某些躯体或精神疾病时较常见到的心理特点,或为其继发症状。述情障碍患者不能适当地表达情绪、缺少幻想,普遍存在于心身疾病、神经症和各种心理障碍的患者中

情障碍主要包括三个方面:

  • 难以识别感觉(DIF),以及难以区分感觉和情绪唤起的身体感觉;
  • 难以向他人描述感受(DDF);
  • 受限的想象过程和外向型认知方式。通常,这三个方面的评估采用20个问题的多伦多述情障碍自我报告量表(TAS-20)。

TAS-20上的每个问题都是1-5分,总分和分类分数的总和分别与述情障碍及其子维度的水平相关。TAS-20总分≥51分被认为具有临床意义,51 - 61分之间代表边缘性述情障碍,≥61分代表述情障碍。超过临床界限的个人被认为患医疗和精神健康疾病的风险增加。虽然由于TAS-20的自我报告性质,其准确性不如临床访谈,但由于其效度高、内外一致性好、给药时间短,被认为是医学研究的“金标准”。在皮肤病学方面,89.2%的综述中确定的研究使用TAS-20评估述情障碍及其亚维度。因此,目前的综述集中在TAS-20评估的皮肤患者述情障碍。

本文主要介绍述情障碍在皮肤科患者中的发病情况,进一步调查述情障碍对疾病负担、社会心理共病和治疗的影响。

方法:利用PubMed、Embase、PsycInfo和Web of Science数据库对2021年3月8日至3月12日期间述情障碍和皮肤疾病进行系统检索。来自合格出版物的数据,包括2008年9月1日以后发表的全文临床研究,以及可用的英文,由两名医科学生提取并总结。

临床显著述情障碍的患病率及其亚型,报告的条件与研究规模描述的数据点的大小,由TAS-20问卷测量。这条粗蓝线作为一般人群中有临床意义的述情障碍患病率的参考。

结果:尽管有少量的文章(n = 37),但数据显示,与健康对照组相比,脱发、白癜风、银屑病、化脓性汗腺炎、特应性皮炎、慢性特发性荨麻疹和原发性局灶性多汗症患者的叙情障碍的患病率和严重程度明显更高。此外,数据一致表明述情障碍、疾病负担和社会心理共病之间存在复杂的相互作用。

结论:识别并解决皮肤科患者述情障碍可改善治疗结果、相关共病和与提高患者的生活质量。

文献来源: Beylot-Barry M,  Mahé E,  Rolland C,Evaluation of the benefit of thermal spa therapy in plaque psoriasis: the PSOTHERMES randomized clinical trial.Int J Biometeorol 2022 Jun;66(6)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1897038, encodeId=6dfd189e0380a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jan 18 00:54:04 CST 2023, time=2023-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798867, encodeId=79801e98867c1, content=<a href='/topic/show?id=a265e065469' target=_blank style='color:#2F92EE;'>#疾病发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70654, encryptionId=a265e065469, topicName=疾病发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Thu Dec 01 09:54:04 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919469, encodeId=9a0c191946938, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Nov 02 08:54:04 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823840, encodeId=f23c1823840a5, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 19 00:54:04 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255385, encodeId=01b81255385c6, content=<a href='/topic/show?id=bd34e2059f1' target=_blank style='color:#2F92EE;'>#皮肤疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72059, encryptionId=bd34e2059f1, topicName=皮肤疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Jul 21 15:54:04 CST 2022, time=2022-07-21, status=1, ipAttribution=)]
    2023-01-18 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=1897038, encodeId=6dfd189e0380a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jan 18 00:54:04 CST 2023, time=2023-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798867, encodeId=79801e98867c1, content=<a href='/topic/show?id=a265e065469' target=_blank style='color:#2F92EE;'>#疾病发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70654, encryptionId=a265e065469, topicName=疾病发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Thu Dec 01 09:54:04 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919469, encodeId=9a0c191946938, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Nov 02 08:54:04 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823840, encodeId=f23c1823840a5, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 19 00:54:04 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255385, encodeId=01b81255385c6, content=<a href='/topic/show?id=bd34e2059f1' target=_blank style='color:#2F92EE;'>#皮肤疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72059, encryptionId=bd34e2059f1, topicName=皮肤疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Jul 21 15:54:04 CST 2022, time=2022-07-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1897038, encodeId=6dfd189e0380a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jan 18 00:54:04 CST 2023, time=2023-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798867, encodeId=79801e98867c1, content=<a href='/topic/show?id=a265e065469' target=_blank style='color:#2F92EE;'>#疾病发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70654, encryptionId=a265e065469, topicName=疾病发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Thu Dec 01 09:54:04 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919469, encodeId=9a0c191946938, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Nov 02 08:54:04 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823840, encodeId=f23c1823840a5, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 19 00:54:04 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255385, encodeId=01b81255385c6, content=<a href='/topic/show?id=bd34e2059f1' target=_blank style='color:#2F92EE;'>#皮肤疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72059, encryptionId=bd34e2059f1, topicName=皮肤疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Jul 21 15:54:04 CST 2022, time=2022-07-21, status=1, ipAttribution=)]
    2022-11-02 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1897038, encodeId=6dfd189e0380a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jan 18 00:54:04 CST 2023, time=2023-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798867, encodeId=79801e98867c1, content=<a href='/topic/show?id=a265e065469' target=_blank style='color:#2F92EE;'>#疾病发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70654, encryptionId=a265e065469, topicName=疾病发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Thu Dec 01 09:54:04 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919469, encodeId=9a0c191946938, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Nov 02 08:54:04 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823840, encodeId=f23c1823840a5, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 19 00:54:04 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255385, encodeId=01b81255385c6, content=<a href='/topic/show?id=bd34e2059f1' target=_blank style='color:#2F92EE;'>#皮肤疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72059, encryptionId=bd34e2059f1, topicName=皮肤疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Jul 21 15:54:04 CST 2022, time=2022-07-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1897038, encodeId=6dfd189e0380a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jan 18 00:54:04 CST 2023, time=2023-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798867, encodeId=79801e98867c1, content=<a href='/topic/show?id=a265e065469' target=_blank style='color:#2F92EE;'>#疾病发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70654, encryptionId=a265e065469, topicName=疾病发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Thu Dec 01 09:54:04 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919469, encodeId=9a0c191946938, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Nov 02 08:54:04 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823840, encodeId=f23c1823840a5, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Mar 19 00:54:04 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255385, encodeId=01b81255385c6, content=<a href='/topic/show?id=bd34e2059f1' target=_blank style='color:#2F92EE;'>#皮肤疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72059, encryptionId=bd34e2059f1, topicName=皮肤疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Jul 21 15:54:04 CST 2022, time=2022-07-21, status=1, ipAttribution=)]

相关资讯

Stroke:动脉瘤性蛛网膜下腔出血后发病率和死亡率的预防

尼莫地平和西洛他唑可能是预防动脉瘤性蛛网膜下腔出血患者发病率和死亡率最有效的治疗方法。克拉森坦、尼卡地平、法舒地尔和镁对迟发性脑缺血和血管痉挛有积极作用,但未发现它们能降低死亡率或致残率。

Ann Intern Med:轻度原发性甲状旁腺功能亢进的死亡率和发病率

甲状旁腺切除术似乎不能降低轻度PHPT患者的发病率或死亡率。因此,在至少10年的时间里,该研究没有观察到与死亡、骨折、癌症、心脑血管事件或肾脏发病率相关的不良影响的证据。

A&R:影像学和症状性手部骨关节炎的患病率、发病率和进展

手部骨关节炎是一种异质性疾病,在年龄、性别、种族、手部症状和受影响的特定关节模式方面存在复杂的差异。有必要进一步研究调查这些差异背后的机制,无论是机械、代谢、荷尔蒙还是体质。

JAMA Dermatol:全球2020年皮肤黑色素瘤的发病率和死亡率

黑色素瘤仍是全球癌症控制和公共卫生的一个重要挑战

每天1.11万国人确诊癌症!国家癌症中心全新报告

肺癌、肝癌、胃癌、结直肠癌和食道癌是癌症死亡的5种原因,占死亡总数的69.3%。不论是发病还是死亡,肺癌均占首位。

Lancet Gastroenterol Hepatol:过去30年全球结直肠癌的发病率和死亡率变化

在全球范围内,从1990年到2019年,结直肠癌病例增加了一倍以上